Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.
Cell
; 181(4): 865-876.e12, 2020 05 14.
Artículo
en Inglés
| MEDLINE | ID: covidwho-684968
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for antiviral approaches that can target emerging viruses with no effective vaccines or pharmaceuticals. Here, we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (prophylactic antiviral CRISPR in human cells), for viral inhibition that can effectively degrade RNA from SARS-CoV-2 sequences and live influenza A virus (IAV) in human lung epithelial cells. We designed and screened CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs targeting SARS-CoV-2. This approach effectively reduced H1N1 IAV load in respiratory epithelial cells. Our bioinformatic analysis showed that a group of only six crRNAs can target more than 90% of all coronaviruses. With the development of a safe and effective system for respiratory tract delivery, PAC-MAN has the potential to become an important pan-coronavirus inhibition strategy.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
ARN Viral
/
Subtipo H1N1 del Virus de la Influenza A
/
Sistemas CRISPR-Cas
/
Betacoronavirus
Tipo de estudio:
Ensayo controlado aleatorizado
Tópicos:
Vacunas
Límite:
Humanos
Idioma:
Inglés
Revista:
Cell
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
J.cell.2020.04.020
Similares
MEDLINE
...
LILACS
LIS